The FDA granted Fast Track designation to TRI-611 for ALK-positive non-small cell lung cancer, a development step for an oral “molecular glue degrader” of ALK fusion proteins. TRI-611 is being developed by TRIANA, with the program aimed at patients who have already received two or more ALK TKIs. The designation is tied to an unmet-need setting where serial resistance remains expected, especially after multiple lines of ALK inhibitor therapy and in the context of central nervous system metastases. Fast Track is intended to expedite development through more frequent FDA interactions and rolling review options, but it is not approval. Mechanistically, the program positions TRI-611 as distinct from kinase inhibitors by degrading ALK fusions independently of ALK’s active site. By recruiting cereblon to drive ubiquitination and proteasomal degradation, the approach could potentially bypass some resistance mechanisms that persist across the kinase class. The move keeps TRI-611 in the spotlight among next-generation targeted therapies aimed at extending options for ALK-rearranged NSCLC patients.